Werewolf Therapeutics (HOWL)
(Delayed Data from NSDQ)
$1.19 USD
-0.02 (-1.65%)
Updated Aug 6, 2025 04:00 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Werewolf Therapeutics, Inc. has a market cap of $53.40M, which represents its share price of $1.19 multiplied by its outstanding shares number of 44.87M. As a small-cap company, HOWL's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
HOWL 1.19 -0.02(-1.65%)
Will HOWL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HOWL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HOWL
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
HOWL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline
Pacira (PCRX) Tops Q4 Earnings Estimates
Other News for HOWL
Werewolf Therapeutics Adopts New Bylaws and Elects Directors
Werewolf Therapeutics (HOWL) Price Target Lowered by BofA, Buy Rating Maintained | HOWL Stock News
Werewolf Therapeutics price target lowered to $9 from $10 at BofA
Werewolf Therapeutics price target lowered by $1 at BofA, here's why
Bank of America Securities Remains a Buy on Werewolf Therapeutics (HOWL)